News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
477,122 Results
Type
Article (38041)
Company Profile (147)
Press Release (438934)
Section
Business (135095)
Career Advice (969)
Deals (21729)
Drug Delivery (92)
Drug Development (54429)
Employer Resources (153)
FDA (13066)
Job Trends (11189)
News (229403)
Policy (22275)
Tag
2024 BioCapital Digital (1)
2024 BioForest Digital (5)
2024 BioForest Standard (1)
2024 BioMidwest Digital (6)
2024 BioMidwest Standard (2)
2024 Bio NC Digital (8)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (10)
2024 Biotech Beach Digital (6)
2024 Biotech Beach Standard (6)
2024 Genetown Standard (5)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (4)
2024 Pharm Country Standard (5)
2025 Lone Star Bio Digital (3)
2026 BioCapital Elite (1)
2026 BioCapital Standard (1)
2026 BioMidwest Elite (2)
2026 Biotech Bay Elite (1)
2026 Biotech Beach Elite (2)
2026 Genetown Elite (2)
2026 Pharm Country Elite (1)
2026 Pharm Country Standard (1)
Academia (2359)
Academic (2)
Accelerated approval (2)
Adcomms (20)
Allergies (73)
Alliances (35393)
ALS (65)
Alzheimer's disease (1020)
Antibody-drug conjugate (ADC) (82)
Approvals (13096)
Artificial intelligence (210)
Autoimmune disease (10)
Automation (10)
Bankruptcy (171)
Best Places to Work (8976)
BIOSECURE Act (13)
Biosimilars (66)
Biotechnology (92)
Bladder cancer (47)
Brain cancer (17)
Breast cancer (199)
Cancer (1470)
Cardiovascular disease (129)
Career advice (851)
Career pathing (31)
CAR-T (94)
Cell therapy (265)
Cervical cancer (17)
Clinical research (44860)
Collaboration (576)
Compensation (173)
Complete response letters (15)
COVID-19 (1897)
CRISPR (21)
C-suite (179)
Cystic fibrosis (62)
Data (1524)
Decentralized trials (2)
Denatured (25)
Depression (38)
Diabetes (180)
Diagnostics (4736)
Digital health (13)
Diversity (8)
Diversity, equity & inclusion (42)
Drug discovery (73)
Drug pricing (72)
Drug shortages (22)
Duchenne muscular dystrophy (58)
Earnings (45239)
Editorial (27)
Employer branding (23)
Employer resources (130)
Events (67867)
Executive appointments (542)
FDA (14011)
Featured Employer (37)
Fibrodysplasia Ossificans Progressiva (1)
Friedreich's ataxia (4)
Frontotemporal dementia (5)
Funding (531)
Gene editing (54)
Generative AI (21)
Gene therapy (179)
GLP-1 (536)
Government (3502)
Grass and pollen (3)
Guidances (40)
Healthcare (14057)
Huntington's disease (15)
IgA nephropathy (18)
Immunology and inflammation (54)
Indications (21)
Infectious disease (1994)
Inflammatory bowel disease (99)
Inflation Reduction Act (8)
Influenza (32)
Intellectual property (59)
Interviews (135)
IPO (9097)
IRA (25)
Job creations (2584)
Job search strategy (752)
Kidney cancer (7)
Labor market (31)
Layoffs (266)
Leadership (9)
Legal (4331)
Liver cancer (61)
Lung cancer (245)
Lymphoma (103)
Machine learning (3)
Management (45)
Manufacturing (164)
MASH (46)
Medical device (13265)
Medtech (13269)
Mergers & acquisitions (12995)
Metabolic disorders (474)
Multiple sclerosis (51)
NASH (19)
Neurodegenerative disease (53)
Neuropsychiatric disorders (12)
Neuroscience (1381)
NextGen: Class of 2025 (4900)
Non-profit (3476)
Northern California (1593)
Now hiring (36)
Obesity (258)
Opinion (131)
Ovarian cancer (59)
Pain (69)
Pancreatic cancer (49)
Parkinson's disease (94)
Partnered (16)
Patents (121)
Patient recruitment (72)
Peanut (41)
People (45646)
Pharmaceutical (36)
Pharmacy benefit managers (11)
Phase I (13162)
Phase II (19481)
Phase III (15825)
Pipeline (703)
Podcasts (38)
Policy (74)
Postmarket research (1849)
Preclinical (4892)
Press Release (64)
Prostate cancer (74)
Psychedelics (27)
Radiopharmaceuticals (179)
Rare diseases (223)
Real estate (4361)
Recruiting (59)
Regulatory (15947)
Reports (46)
Research institute (2041)
Resumes & cover letters (132)
Rett syndrome (2)
RNA editing (2)
RSV (33)
Schizophrenia (54)
Series A (95)
Series B (59)
Service/supplier (8)
Sickle cell disease (34)
Southern California (1324)
Special edition (11)
Spinal muscular atrophy (118)
Sponsored (22)
Startups (2985)
State (1)
Stomach cancer (12)
Supply chain (41)
The Weekly (12)
United States (14677)
Vaccines (447)
Venture capitalists (29)
Webinars (11)
Weight loss (174)
Women's health (22)
Worklife (14)
Date
Today (159)
Last 7 days (509)
Last 30 days (1936)
Last 365 days (24000)
2025 (5668)
2024 (25301)
2023 (28953)
2022 (37466)
2021 (40563)
2020 (39143)
2019 (34858)
2018 (26366)
2017 (23661)
2016 (22965)
2015 (26454)
2014 (19994)
2013 (16934)
2012 (18404)
2011 (18725)
2010 (17400)
Location
Africa (528)
Alabama (32)
Alaska (5)
Arizona (143)
Arkansas (10)
Asia (29052)
Australia (4856)
California (3571)
Canada (1398)
China (390)
Colorado (168)
Connecticut (185)
Delaware (109)
Europe (62241)
Florida (620)
Georgia (138)
Hawaii (1)
Idaho (39)
Illinois (390)
India (23)
Indiana (260)
Iowa (5)
Japan (113)
Kansas (75)
Kentucky (16)
Louisiana (7)
Maine (31)
Maryland (665)
Massachusetts (2638)
Michigan (150)
Minnesota (310)
Mississippi (2)
Missouri (55)
Montana (19)
Nebraska (20)
Nevada (34)
New Hampshire (65)
New Jersey (1217)
New Mexico (21)
New York (1141)
North Carolina (683)
North Dakota (8)
Northern California (1593)
Ohio (148)
Oklahoma (8)
Oregon (26)
Pennsylvania (867)
Puerto Rico (7)
Rhode Island (24)
South America (726)
South Carolina (18)
Southern California (1324)
Tennessee (78)
Texas (549)
Utah (123)
Virginia (88)
Washington D.C. (44)
Washington State (284)
West Virginia (3)
Wisconsin (52)
477,122 Results for "nerviano medical sciences nervianoms".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Nerviano Medical Sciences Announces Enhanced US Executive Team
Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group), focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, announced today the expansion of and transition in its executive team of its wholly owned U.S. subsidiary (Nerviano Medical Sciences, Inc./ NMS-US) in Boston.
August 1, 2023
·
3 min read
Nerviano Medical Sciences and Italfarmaco Announce Licensing of Linker-Payload Technology to Develop and Commercialize a Novel Peptide-Drug Conjugate
Nerviano Medical Sciences S.r.l., a clinical-stage biotechnology company member of NMS group, announced the signing of a license agreement with Italfarmaco S.p.A., a specialty pharmaceutical company, to develop and commercialize a novel peptide-drug conjugate.
December 14, 2023
·
5 min read
Drug Development
Nerviano Medical Sciences to Present Preliminary Phase 1 PARP1 selective inhibitor data at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nerviano Medical Sciences S.r.l., and Nerviano Medical Sciences, Inc. announced today it will present initial data from the PARP1 inhibitor Phase 1 studies at the upcoming AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, being held October 11-15 in Boston, MA.
October 2, 2023
·
3 min read
Drug Development
Nerviano Medical Sciences Presents Preliminary, Encouraging Clinical Phase 1 Data for PARP-1 Selective Inhibitor at the 35th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Nerviano Medical Sciences S.r.l., a part of NMS Group S.p.A. (NMS Group) and Nerviano Medical Sciences, Inc., a wholly owned subsidiary of NMS Group, focused on the discovery and early development of oncology drugs and the largest oncological R&D company in Italy, reported today, initial results from the dose escalation parts of two Phase I-I/II studies for NMS-03305293 (NMS-293).
October 12, 2023
·
5 min read
Business
Nerviano Medical Sciences Announces Licensing of Linker-Payload Technology to Solve Therapeutics to Develop and Commercialize Novel Antibody-Drug Conjugates.
Nerviano Medical Sciences S.r.l. (NMS) announced signing of a license agreement and right of option with Solve Therapeutics, Inc. (SolveTx) to develop and commercialize novel antibody-drug conjugates (ADCs) for up to four cancer targets selected by SolveTx.
June 5, 2023
·
6 min read
Business
Nerviano Medical Sciences Strengthens Executive Team to Maximize IDH1/IDH2 Inhibitor Asset
Nerviano Medical Sciences S.r.l. announced the senior appointment to drive validation and maximize the value of its IDH1/IDH2 Inhibitor Asset, NMS-173, and facilitate its expanding and advancing clinical pipeline.
January 12, 2023
·
5 min read
Business
Nerviano Medical Sciences S.r.l. Announces Collaboration and Option to License Agreement with Merck
Nerviano Medical Sciences S.r.l. announced today the signing of a collaboration agreement with licensing option with Merck Healthcare KGaA (Merck), for the next-generation highly selective and brain penetrant PARP1 inhibitor NMS-293.
September 21, 2022
·
5 min read
Business
Merck KGaA, Darmstadt, Germany Enters Collaboration and Option to License Agreement with Nerviano Medical Sciences to Develop Next-Generation PARP1 Selective Inhibitor
Merck KGaA, Darmstadt, Germany, a leading science and technology company, today announced a collaboration agreement with licensing option with Nerviano Medical Sciences S.r.l. (NMS) for the next-generation highly selective and brain-penetrant PARP1 (poly (ADP-ribose) polymerase) inhibitor, NMS-293.
September 21, 2022
·
4 min read
Job Trends
Report: 2025 U.S. Life Sciences Salary Report
March 25, 2025
·
1 min read
·
BioSpace Insights
Venture capitalists
Blackstone Launches New $5B+ Fund for Life Sciences
Blackstone joins other big investors such as ARCH Venture Partners and Bain Capital Life Sciences in pumping billions of dollars into the industry.
January 31, 2025
·
2 min read
·
Tristan Manalac
1 of 47,713
Next
